Norton Rose Fulbright plays a key role in several prominent U.S. antitrust matters, addressing significant issues involving generic pharmaceutical products, algorithmic price-fixing, ‘no-poach’ agreements, and the big tech sector. The group is a trusted advisor to clients involved in class actions, MDL litigation, and criminal antitrust matters in both federal and state courts. In Washington DC, co-chair Robin Adelstein’s extensive antitrust expertise is enhanced by her background in the pharmaceutical sector. Co-chair Neeley Agin rejoined the DC office in March 2024. Based in Houston, Layne Kruse leads litigation and investigations across the energy, life sciences, insurance, and transportation sectors.
Legal 500 Editorial commentary
- Profile
Key clients
- Office of the Attorney General of Texas
- Phillips 66
- Kairoi Management
- Creekwood Property Corporation
- Irico Display Devices
- American Contractors Indemnity Company
- Zhuhai Cos
- Republic National Distributing Company
- Cinemark
Work highlights
Representing an international pharmaceutical company in re: Generic Pharmaceuticals Pricing Antitrust Litigation.
Represented Phillips 66 in this putative antitrust class action, Persian Gulf Inc. v. BP West Coast Products.
Lawyers
Practice head
Robin Adelstein; Neely Agin
Other key lawyers
Layne Kruse; Darryl Anderson; Michael Swartzendruber; Mark Robertson; Eliot Turner; Geraldine Young